logo-loader
RNS
Silence Therapeutics PLC

Silence Therapeutics - Notice of Results

RNS Number : 3199F
Silence Therapeutics PLC
20 February 2018
 

 

Silence Therapeutics Notice of Results

 

London, 20th February 2018

 

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce its Preliminary Results for the twelve months ended 31st December, 2017 on Tuesday 6th March 2018.

 

Ali Mortazavi, Chief Executive Officer and David Ellam, Chief Financial Officer, will host a presentation for analysts at 9:00am on the day of the results at the Devonshire Club, 5 Devonshire Square, London EC2M 4YD.

 

Enquiries:

 

Silence Therapeutics plc

Ali Mortazavi, Chief Executive Officer

David Ellam, Chief Financial Officer

Tel:  +44 (0)20 3457 6900

 

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson

 

Tel:  +44 (0)20 7418 8900

Media Enquiries:

 

Optimum Strategic Communications 

Mary Clark/ Eva Haas/Hollie Vile

silence@optimumcomms.com

 

 

Tel: +44 (0) 20 3714 17

Notes to Editors

 

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORZMGMZNLVGRZM
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read